SEARCH

SEARCH BY CITATION

References

  • Bell, H., Hellum, K., Harthug, S., Maeland, A., Ritland, S., Myrvang, B., Von Der Lippe, B., Raknerud, N., Skaug, K., Gutigard, B.G., Skjaerven, R., Prescott, L.E., Simmonds, P. & Group, C. (1997) Genotype, viral load and age as independent predictors of treatment outcome of interferon-α2a treatment in patients with chronic hepatitis C. Scandinavian Journal of Infectious Disease, 29, 1722.
  • Chan, S.W., McOmish, F., Holmes, E.C., Dow, B., Peutherer, J.E., Follett, E., Yap, P.L. & Simmonds, P. (1992) Analysis of a new hepatitis C virus type and its phylogenetic relationship to existing variants. Journal of General Virology, 73, 11311141.
  • Clemente, M.G., Congia, M., Lai, M.E., Lilliu, F., Lampis, R., Frau, F., Frau, M.R., Faa, G., Diana, G., Dessi, C., Melis, A., Mazzoleni, A.P., Cornacchia, G., Cao, A. & De Virgiliis, S. (1994) Effect of iron overload on the response to recombinant interferon-alfa treatment in transfusion-dependent patients with thalassemia major and chronic hepatitis C. Journal of Pediatrics, 125, 123128.
  • Di Marco, V., Lo lacono, O., Almasio, P., Ciaccio, C., Capra, M., Rizzo, M., Malizia, R., Maggio, A., Fabiano, C., Barbaria, F. & Craxi, A. (1997) Long-term efficacy of α-Interferon in β-thalassaemia with chronic hepatitis C. Blood, 90, 22072212.
  • Donohue, S.M., Wonke, B., Hoffbrand, A.V., Reittie, J., Ganeshaguru, K., Scheuer, P.J., Brown, D. & Dusheiko, G. (1993) Alpha interferon in the treatment of chronic hepatitis C infection in thalassaemia major. British Journal of Haematology, 83, 491497.
  • EASL International Consensus Conference on Hepatitis C (1999) Consensus Statement. Journal of Hepatology, 30, 956961.
  • Lai, M.E., De Virgilis, S., Argiolu, F., Farci, P., Mazzoleni, A.P., Lisci, V., Rapicetta, M., Clemente, M.G., Nurchis, P., Arnone, M., Balestrieri, A. & Cao, A. (1993) Evaluation of antibodies to hepatitis C virus in a long-term prospective study of posttransfusion hepatitis among thalassemic children: comparison between first- and second-generation assay. Journal of Pediatric Gastroenterology and Nutrition, 16, 458464.
  • Ohno, O., Mizokami, M., Wu, R.R., Saleh, M.G., Ohba, K., Orito, E., Mukaide, M., Williams, R. & Lau, J.Y. (1997) New hepatitis C virus (HCV) genotyping system that allows for identification of HCV genotypes 1a, 1b, 2a, 2b, 3a, 3b, 4, 5a, and 6a. Journal of Clinical Microbiology, 35, 201207.
  • Poynard, T., Marcellin, P., Lee, S.S., Niederau, C., Minuk, G.S., Ideo, G., Bain, V., Heathcote, J., Zeuzem, S., Trepo, C. & Albrecht, J. (1998) Randomised trial of interferon α 2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet, 352, 14261432.
  • Telfer, P.T., Garson, J.A., Whitby, K., Grant, P.R., Yardemian, A., Hoffbrand, A.V. & Wonke, B. (1997) Combination therapy with interferon alpha and ribavirin for chronic hepatitis C virus infection in thalassaemic patients. British Journal of Haematology, 98, 850855.
  • Zeuzem, S., Feinman, S.V., Rasenack, J., Heathcote, J., Lai, M.Y., Gane, E., O'Grady, J., Reichen, J., Diago, M., Lin, A., Hofman, J. & Brunda, M.J. (2000) Peginterferon Alfa-2a in patients with chronic hepatits C. New England Journal of Medicine, 343, 16661672.